<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043923</url>
  </required_header>
  <id_info>
    <org_study_id>NKT-202</org_study_id>
    <nct_id>NCT04043923</nct_id>
  </id_info>
  <brief_title>Norketotifen for the Treatment of Uncomplicated Influenza-like Illness</brief_title>
  <official_title>A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergo Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergo Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled,
      parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute
      uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to alleviation of symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Time to alleviation of the symptoms of ILI (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose symptoms have been alleviated at each time point through Day 5</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in composite symptom score at each time point through Day 5</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever (body temperature equal to or less than 37ºC)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature at each time point through Day 5</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to alleviation of individual symptoms (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resumption of normal activity</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication (acetaminophen)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Influenza -Like Illness</condition>
  <arm_group>
    <arm_group_label>Norketotifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norketotifen oral capsules, once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsules, once daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norketotifen</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Norketotifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to understand the study and comply with all study procedures, and willing to
             provide written informed consent prior to the pre-dose examinations

          2. Symptoms of ILI including all of the following:

               -  Fever ≥38º Celsius (oral) in the predose examinations or &gt;4 hours after dosing of
                  antipyretics if they were taken

               -  At least one of the following general systemic symptoms associated with ILI are
                  present with a severity of moderate or greater: headache, feverishness or chills,
                  muscle or joint pain, fatigue

               -  At least one of the following respiratory symptoms associated with ILI are
                  present with a severity of moderate or greater: cough, sore throat, nasal
                  congestion

          3. The time interval between the onset of symptoms and the predose examinations is ≤96
             hours. The onset of symptoms is defined as either:

               -  Time of the first increase in body temperature (an increase of at least 1º
                  Celsius from normal body temperature)

               -  Time when the subject experiences at least one general or respiratory symptom

          4. Females of childbearing potential and males agree to use an appropriate method of
             contraception as detailed in the protocol

        Exclusion Criteria:

          1. Female subjects who are pregnant, 2 weeks post-partum, or breastfeeding

          2. Severe ILI requiring inpatient treatment

          3. Any of the following risk factors (according to the CDC's list of People at High Risk
             for Developing Serious Flu-Related Complications):

               -  Residents of nursing homes or other long-term care facilities

               -  American Indians and Alaska natives

               -  Asthma

               -  Chronic lung disease (such as chronic obstructive pulmonary disease or cystic
                  fibrosis)

               -  Neurological and neurodevelopmental conditions (including disorders of the brain,
                  spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy
                  [seizure disorders], stroke, intellectual disability, moderate to severe
                  developmental delay, muscular dystrophy, or spinal cord injury)

               -  Heart disease (such as congenital heart disease, congestive heart failure, or
                  coronary artery disease)

               -  Blood disorders (such as sickle cell disease)

               -  Endocrine disorders (such as diabetes mellitus)

               -  Kidney disorders

               -  Liver disorders

               -  Metabolic disorders (such as inherited metabolic disorders and mitochondrial
                  disorders)

               -  Compromised immune system due to disease or medication (such as subjects with
                  human immunodeficiency virus or cancer, or those on chronic steroids)

               -  Extreme obesity (body mass index ≥40 kg/m^2)

          4. Presence of any severe or uncontrolled medical or psychiatric illness

          5. History of or current autoimmune disease

          6. History of recurrent lower respiratory tract infection

          7. Any concurrent infection requiring systemic antimicrobial and/or antiviral therapy

          8. Female subjects who are pregnant or breastfeeding

          9. Any clinically significant electrocardiogram test

         10. Received baloxavir, oseltamivir, peramivir, zanamivir, rimantadine, or amantadine
             within 30 days prior to the pre-dose examinations

         11. Received an investigational monoclonal antibody for a viral disease in the last year
             prior to the pre-dose examinations

         12. Received ketotifen fumarate, cromolyn sodium, or nedocromil sodium by any route of
             administration within 30 days prior to the pre-dose examinations

         13. Exposure to an investigational drug within 30 days prior to the pre-dose examinations

         14. History of allergic reaction to ketotifen

         15. Any prior exposure to norketotifen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emergo Therapeutics Clinical Trials</last_name>
    <phone>984-377-5151</phone>
    <phone_ext>204</phone_ext>
    <email>ClinicalTrial@emergotherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cahaba Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Trials AZ</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Long Beach Clinical Trial Services</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AFC Urgent Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Florida Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Research Associate</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Medical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Family Physicians</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Medicine Associates of Texas</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CityDoc Urgent Care</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Village Health Partners</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

